Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: Safety and dialysability

American Journal of Roentgenology

Volumn 178, Issue 1, 2002, Pages 105-109

  Tombach, B ^a   Bremer, C ^a   Reimer, P ^a   Matzkies, F ^a   Schaefer, R M ^a   Ebert, W ^a   Geens, V ^a   Eisele, J ^a   Heindel, W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIALYSIS MEMBRANE; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0036135655     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.178.1.1780105     Document Type: Article

References (32)

1. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast
2. Clearance of gadolinium chelates by hemodialysis: An in vitro study
3. Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency
4. Safety of gadolinium-DTPA: Extended clinical experience
5. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure
6. Pharmacocinetics of Gd-DTPA in patients with chronic renal failure
7. Functional dynamic MRI, pharmacocinetics and safety of Gd-DTPA in patients with impaired renal function
8. Gadodiamide in renal transplant patients: Effects on renal function and usefulness as a glomerular filtration rate marker
9. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis
10. Safety of pro hance in special populations
11. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience
12. Pharmakokinetik von gadolinium-DTPA bei dialysepflichtiger chronischer niereninsuffizienz
13. Elimination of gadolinium-DTPA by peritoneal dialysis
14. Gadopentetate dimeglumine enhanced MRI in an anephric patient on dialysis
15. Elimination of Gd-DTPA by means of hemodialysis
16. Magnetic resonance imaging contrast agents design and physicochemical properties of gadodiamide
17. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent
18. Pre-clinical evaluation of gadobutrol: A new, neutral, extracellular contrast agent for magnetic resonance imaging
19. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers
20. Perfusion-weighted MRI using gadobutrol as a contrast agent in a rat stroke model
21. Assessment of myocardial perfusion using contrast-enhanced MR imaging: Current status and future developments
22. Does a higher concentration of gadolinium chelates improve first-pass cardiac signal changes?
23. High-dose applications of gadolinium chelates in magnetic resonance imaging
24. Experience with high dose gadolinium MR imaging in the evaluation of brain tumors
25. MR enhancement of brain lesions: Increased contrast dose compared with magnetization transfer
26. Sicherheit und nutzen von gadobutrol bei patienten mit zerebralen tumoren (phase-III-studie)
27. Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma
28. Subclavian MR arteriography: Reduction of susceptibility artifact with short echo time and dilute gadopentetate dimeglumine
29. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: Results of a randomized study
30. Permeability of gadolinium-DTPA through two types of hemodialysis membrane
31. Permeability of contrast media through hemodialysis membrane
32. The dialysability of Gd-DTPA